| HS Code | 781517 |
| Chemical Name | tert-butyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate |
| Molecular Formula | C13H24O5 |
| Molecular Weight | 260.33 g/mol |
| Cas Number | 161640-75-7 |
| Appearance | Colorless oil |
| Purity | Typically >98% |
| Boiling Point | No data available |
| Density | No specific data reported |
| Smiles | CC(C)(C)OC(=O)C1COC(CO)OC1(C)C |
| Inchi | InChI=1S/C13H24O5/c1-12(2,3)17-11(16)8-7-18-13(4,5)9(6-14)10(8)15/h8-10,14-15H,6-7H2,1-5H3/t8-,9+,10- |
As an accredited tert-butyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | The 5g sample is supplied in a sealed amber glass bottle with a tamper-evident cap, labeled with chemical details and hazard warnings. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL): Securely packs tert-butyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate in sealed drums, ensuring safe transit. |
| Shipping | This chemical is shipped in a tightly sealed, inert container to prevent contamination and moisture absorption. It is typically transported at ambient temperature with protection from light and excessive heat. Proper chemical labeling and accompanying safety documentation are included to comply with regulatory standards and ensure safe handling upon delivery. |
| Storage | Store **tert-butyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate** in a tightly sealed container, protected from moisture and light, at room temperature (15–25 °C) in a dry, well-ventilated area. Keep away from strong acids, bases, and oxidizing agents. Ensure appropriate labeling, and store separately from incompatible substances. Follow standard laboratory chemical storage protocols and use in a fume hood if required. |
| Shelf Life | Shelf life: Store at 2–8°C, protected from light and moisture; chemically stable for at least 2 years under proper conditions. |
As an experienced manufacturer of specialized carbohydrate derivatives, we supply tert-butyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate to innovators in advanced synthesis applications. Its unique protecting group functionality and high stereochemical purity have been adopted by several industrial sectors demanding consistent quality, defined reaction control, and regulated batch integrity. Below, we outline the primary downstream application scenarios where this material has been adopted, highlighting regulatory standards, usage ratios, integration into production processes, and resulting end products from our customers’ operations.
Contemporary small-molecule drug production—particularly for nucleoside or nucleotide analogues used in antiviral and anticancer therapeutics—deploys this protected carbohydrate as a core glycosyl donor. Its specific structure supports stereo-controlled glycosylation steps required for constructing the chiral sugar moiety of modified nucleosides. Formulators choose this intermediate to ensure reliable downstream deprotection and purification, which is critical for GMP batch consistency in high-value pharmaceutical actives.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Downstream veterinary pharmaceutical operations integrate this material as a critical glycosyl precursor during the scale-up of specialty veterinary drugs, especially those mimicking mammalian carbohydrate structures for improved solubility and absorption in animal health formulations. The defined tert-butyl and dioxane protection enables chemists to manage reaction selectivity and achieve high-purity intermediates, supporting compliance with specific veterinary medicine production guidelines.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Manufacturers producing therapeutic oligonucleotides leverage this compound as a protected sugar starting block in solid-phase synthesis workflows. The unique protecting pattern assures compatibility with automated DNA/RNA synthesizers, minimizing side reactions during sequential coupling cycles. Its selective deprotection and stability help molecular biologists construct complex oligonucleotide chains used in RNA therapeutics, gene editing tools, and diagnostic probes.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Specialty fine chemical workshops and research facilities utilize this protected carbohydrate as a foundational intermediate for synthesizing novel carbohydrate molecules, which serve as biochemical research tools, analytical standards, or as probes in glycoscience. Its well-characterized stereochemistry and compatibility with multiple modification pathways make it favored for customized, small-volume batch synthesis and structural diversification, ensuring traceable lot-to-lot identity and data reproducibility for scientific investigations.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive tert-butyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618005193850 or mail to sales8@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8618005193850
Email: sales8@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Bringing tert-butyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate to life in our facility has taught us a great deal about the delicate interplay between process efficiency and product consistency. Small variations in temperature or solvent purity have a direct impact on optical purity and yield. Our plant teams pay close attention to every reaction parameter, since even small deviations during hydrolysis or protection steps can skew the chiral outcome. Batch after batch, we take care to verify enantiomeric excess using chiral chromatography because in many applications, a small impurity can carry downstream—in synthesis, in active pharmaceutical ingredient (API) intermediates, or in fine chemicals.
A lot happens behind the scenes before our tert-butyl-2-acetate leaves the drum. Teams monitor every reactor charge, sample collection point, and drying step. Our workforce adjusts timelines and flow rates by hand in response to real lab data, not spreadsheets. This practice keeps levels of key contaminants, like unreacted starting materials and dioxane ring cleavage byproducts, far below accepted limits. We believe discipline at the bench produces cleaner product at scale, with users downstream seeing the difference in their own reaction yields.
Chemists working on multi-step syntheses often need building blocks that offer both steric bulk and tailored reactivity. tert-Butyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate fits this need because its dioxane core protects sensitive alcohols while the tert-butyl and acetate groups provide handles for further elaboration. Staff chemists report less undesired side-reactions when using this protected secondary alcohol compared to less hindered alternatives. The dioxane’s cage structure shields the hydroxymethyl arm, making it an excellent intermediate for routes that would destroy or modify unprotected alcohols.
The compound’s particular stereochemistry—(4R,6S)—has proven essential in asymmetric synthesis, especially when the downstream product’s biological activity hinges on a certain configuration. Transferring those chiral centers reliably means the manufacturing route has to minimize racemization both in main steps and purification. Not every company has the patience or experience to shepherd these centers all the way from raw substrate to packed drum. We built our methods over years of collaboration with the leading process chemists in the business and test every lot against standards developed with end users.
Pharmaceutical clients, including those developing complex nucleotide analogues or sugar-based drugs, prefer this material for its ratio of reactivity to stability. Synthetic researchers have told us that weaker protecting groups fall apart under mild acid or prolonged heating. In our own technical service lab, we have compared dioxane-based protection with simpler acetonide-based alternatives and found dioxane outperforms in keeping the alcohol protected during base wash steps, as well as scale-up crystallizations. The additional steric bulk of the tert-butyl group makes downstream deprotection more selective—users reclaim a higher percentage of their valuable core structure without extra scavenge or alkali work-up.
Compared to simple methyl or ethyl esters, tert-butyl esters built onto this dioxane system give greater hydrolytic stability during extended processing. We have seen this in actual campaign work, where extended dissolutions or delayed workups will erode weaker esters, causing yield loss and fouling. The acetate moiety adds a measured level of reactivity, which can be cleaved cleanly under standard deprotection without generating hard-to-remove side products.
Biotech customers working on carbohydrate chemistry have come back to us noting how the chiral purity and functional group protection made the difference between hit-and-miss research and reproducible results. One outfit ran back-to-back syntheses using a competitor’s batch and our material: side-by-side HPLC showed tighter peaks and a single enantiomer in our batch. The difference was more than academic. Their route output jumped, waste solvent and column load dropped, and they requested follow-up supply in short order.
Process operators in our plant highlight the importance of dry, low-temperature storage—even modest moisture uptake can cause partial hydrolysis or ring opening, which sneaks into the final product as unwanted peaks on QA reports. We implemented nitrogen blanketing not out of habit, but in direct response to a run where atmospheric moisture spiked the hydrolysis side-reaction. As a result, our packaging line stays under strict atmospheric control until every drum is sealed.
We found that this compound crystals out best from certain polar solvents. Early in development, we struggled with sticky cake formation and slow drying. Tweaking the final wash solvent and increasing tray airflow significantly improved yield and reduced stubborn solvent residues. Experienced operators learned to test mother liquors for uncrystallized product, which helps minimize losses at this costly stage.
tert-Butyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate isn’t just a mouthful to say. Its structure sets it apart. Products with similar names sometimes swap out the dioxane for simpler cyclic or acyclic protections. Differences show up quickly in trial reactions. The rigid ring on our product means less risk of rotation, less isomerization, and no unpredictable loss of configuration, even after weeks on the bench.
Many intermediates in the market cut costs by relaxing control on stereochemistry or sacrificing purity at the isolation stage. We stick with strict optical rotation and chromatographic checks, since any slip can ruin a customer’s late-stage coupling reactions or bioactivity screening. Over the years, we’ve seen that customers value relationships with manufacturers who sweat these details rather than push “good enough” batches at scale.
We have heard purchasing teams mention price as a differentiator, but technical buyers report far more concern over reproducibility, stereochemical control, and minimal impurities. For high-value syntheses, a few pennies saved do not justify headaches downstream. That is why our production and QC focus on purity, not just cost per kilo metrics. Plenty of alternative dioxane acetates float around the market, but few are tailored for the precise, repeatable needs of sensitive chiral assembly, as is often demanded in lead candidate and scale-up drug projects.
We often get questions about the nature of our product compared to catalog and broker-sourced offerings. Working as a manufacturer, we gain first-hand feedback from our customers, then apply it back into our process line. When customers report downstream breakthroughs or run into bottlenecks, we host follow-up calls between production and their project leads. Lessons learned go back into the next lot: whether that means a change in filter medium, a tweak to recrystallization, or a shift in QC analysis to better catch impurity drift.
This tight feedback cycle changes the equation compared to big-box or distributor chemicals. Many buyers do not see the impact until they scale fast—one off-grade intermediate, and whole montages of late-stage chemistry slow or stall. By keeping production, QA, and packaging under one roof, we take responsibility for what leaves our site, and can stand by both data and performance at scale. For researchers under pressure to deliver phase-boundary intermediates on deadline, this direct feedback saves lost time and budget.
Longer shelf-life also marks a key advantage. By controlling synthetic, purification, and packaging routes, we optimize water and oxygen exposure. No third-party repackaging, which can let air sneak in and shave months off practical storage life. As a result, our drums deliver reliably from the first batch to the last, even if a project’s pathway changes or pauses mid-stream.
Technical buyers ask detailed questions about starting material origins, levels of trace contaminants, and validation of analytical methods. Our transparency and open-door policy let customers see actual analytic runs: they want to hear about impurities below percent levels, not just broad-stroke certificates. Over time, that clarity breeds trust—process chemists learn what signals to check, which ghosts to watch for, and how to adapt their downstream processes in case of shifts. Twice a year, we update our analytical panels to match new regulatory triggers or customer feedback.
This compound acts as a litmus test for intermediate manufacturers. If you cannot deliver clean, well-characterized tert-butyl 2-acetate, it suggests weaknesses all along the line, from operator discipline to lab oversight. That’s true not just for this molecule, but for everything else that runs through those vessels.
One recurring challenge in production and user environments comes from the slow, creeping impact of cross-contamination and cumulative impurities—either from repeated re-use of process vessels or shifts in upstream raw material purity. We address this by allocating dedicated lines whenever possible and conducting regular deep cleans supervised by experienced plant chemists, not just operators. Instead of relying only on end-product analysis, we sample intermediates after each significant step.
The complexity of this molecule, especially with two chiral centers and a tendency toward ring closure/opening equilibria, prompts constant vigilance. We monitor for trace side-products with advanced LC-MS and adjust reaction quench and workup procedures where new fragments appear. Feedback loops from our largest pharmaceutical customers have prompted us to develop in-process chiral GC checks, which flag drift long before a full batch is compromised. Even if schedule pressure tempts shortcuts, long-term experience shows that losing a batch to contamination costs more than any saved time.
We continue to invest in analytical automation, so lot release runs smoother and faster—and users get material sooner after order. Our data archiving lets us trace any batch fully backward, which supports both process improvement and customer assurance in case of rare anomalies.
As demand grows for this and other complex protected building blocks, manufacturers face pressure on both speed and quality. Automation, better in-line sensing, and experienced process chemists help align these goals. Still, years at the process line have taught us to trust data, not tradition—what worked last year might not survive shifts in raw material supply or regulatory update. We treat each production campaign as both a continuation and a test.
We keep a close dialogue with those using our material in high-impact drug and fine chemical routes. Their insights return as process tweaks—sometimes as small as a modified filter pore or adjusted crystallization sequence—so each campaign runs a bit cleaner, a bit more robustly. In practical terms, innovations like continuous-flow protection and more selective catalysts have reduced energy and solvent use, which benefits not just customers but our own staff and the local environment. These changes show in both environmental KPIs and lot-to-lot consistency on the plant floor.
We see the world moving toward more structurally complex, chiral-rich candidates in drug and advanced material pipelines. The future will not favor generic, low-detail supply chains for complex intermediates. Instead, chemists and buyers gravitate to suppliers who share process control details, enable transparent QA, and respond rapidly to shifts in project needs. Having direct production oversight positions us to adapt—shifting campaigns, scaling custom runs, and building out analytical capacity in response to what customers actually report from their benches.
Ongoing investment in both human expertise and technical upgrades makes the difference. Staff know their lines—and they know how the tiniest change can ripple. By treating every drum of tert-butyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate as both a product and a promise, we deliver confidence to project teams relying on each kilogram. As molecules grow more elaborate, equipment and human insight must keep pace, or risk holding back innovation.
Our experience over many campaigns with tert-butyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl) acetate comes down to a few key lessons. Rigorous control at every step, close tracking of chiral and impurity profiles, responsive manufacturing practice, and honesty with customers make all the difference for real-world project success. We continue to view every new batch—and every feedback report from our partners—as a chance to do better on every front.